GATM

Your body builds creatine, the molecule that powers fast bursts of cellular energy, through a two-step assembly line. GATM (glycine amidinotransferase) runs the first step of that line. When the gene that codes for this enzyme carries certain variants, the consequences can show up in unexpected places: your kidneys, your muscles, or your response to a common cholesterol medication.

This is a research-stage genetic marker. There are no standardized clinical cutpoints, and a single result will not give you a clean diagnosis. What it can do is flag whether you carry variation in a gene tied to creatine biosynthesis, kidney function, and statin response, which can prompt more focused follow-up if other parts of your health picture line up.

What This Gene Actually Does

Creatine is made in two steps. The first step combines two amino acids, arginine and glycine, into a molecule called guanidinoacetate (GAA). GATM is the gene that codes for the enzyme (called AGAT) that does this first step. A second enzyme then converts GAA into creatine, which feeds the energy-buffering system that keeps your muscles, brain, and other high-demand tissues working.

GATM is expressed in tissues that need a steady creatine supply, including the placenta, where it sits in the cells lining blood vessels. Its activity responds to hormones and to the supply of arginine and other building blocks, which is one reason creatine demand and production shift during pregnancy and other high-energy states.

Kidney Function and Disease Progression

A Mendelian randomization study using mitochondrial-related genome-wide data analyzed GATM gene variants and found that higher GATM expression was linked to a lower risk of chronic kidney disease and positively correlated with kidney filtration rate (eGFR), a standard measure of how well your kidneys clear waste. This suggests GATM may be a potential therapeutic target rather than just a passive marker.

A separate line of research identified rare single-copy mutations in GATM that cause a kidney disease called renal Fanconi syndrome, which can progress to kidney failure. In studies of affected families, these mutations led to abnormal protein deposits inside kidney cells, triggering scarring (fibrosis) and gradual loss of function. This is a rare cause of kidney disease, but it shows that GATM variants can directly damage the kidney rather than only shifting risk at the margins.

What this means for you: if you carry a GATM variant and your kidney filtration rate is drifting downward over time, the gene may be one piece of the picture. Pairing this result with serial eGFR and cystatin C measurements is more informative than reading any single number in isolation.

Statin-Induced Muscle Symptoms

GATM first drew attention in cardiology because a specific variant (rs9806699) was reported to lower the risk of muscle pain and damage from statin therapy. A follow-up case-control study in 715 people with high cholesterol could not replicate this finding, meaning the association did not hold up in a larger, more diverse group.

A separate systematic review noted that a different GATM variant (rs1719247) was linked to about 40% lower odds of statin-related muscle symptoms (odds ratio 0.60) when those symptoms were defined as muscle pain combined with elevated creatine kinase, a blood marker of muscle injury. The evidence is mixed, but GATM remains one of the genes researchers look at when trying to understand why some people tolerate statins and others do not.

Reconciling the Mixed Statin Findings

The two statin studies seem to disagree, but they are not actually in conflict. They looked at different GATM variants, and the more cautious read is that GATM variation may nudge statin tolerance in some subgroups while having no detectable effect in others. This is not a marker that tells you whether you will react badly to a statin. It is a piece of background biology that may matter more in combination with other pharmacogenetic markers like SLCO1B1, which has a much stronger and more reproducible link to statin myopathy.

The Creatine Biosynthesis Connection

GATM sits in the same biological pathway as GAMT, the enzyme that catalyzes the second step of creatine synthesis. Severe genetic loss of either enzyme causes a rare inherited disorder called a cerebral creatine deficiency, marked by developmental delay, seizures, and movement problems in children. AGAT (GATM) deficiency is the less common of the two and often presents with muscle weakness in addition to neurological symptoms. These are pediatric diseases diagnosed in childhood, not adult-onset conditions detected by routine testing. They are mentioned here only because they show what happens when the GATM enzyme is essentially absent.

Pregnancy and Placental Energy Demands

GATM and the rest of the creatine pathway are highly active in the placenta. Studies of placental tissue have found that early-onset pre-eclampsia is associated with changes in GATM expression and placental creatine content, while pregnancies complicated by fetal growth restriction show lower GATM expression in late gestation. These findings come from research on placental tissue, not blood-based GATM testing, so they do not directly translate to what your own gene test result means. They do suggest that creatine metabolism is a relevant axis in pregnancy biology.

Why One Reading Is Not Enough

Genetic results do not change over time. The variant you carry today is the variant you will carry in ten years. What does change is your interpretation of that variant, because GATM is an active area of research and the clinical meaning of specific variants is still being refined.

The retesting that matters here is not the gene itself but the downstream measurements that reveal whether your GATM biology is producing any visible effect. Tracking eGFR, cystatin C, and urinary protein every 6 to 12 months tells you whether kidney function is drifting. Tracking creatine kinase periodically, especially if you start a statin, tells you whether muscle stress is showing up. A baseline GATM result combined with serial functional measurements gives you a much sharper picture than either alone.

What To Do With an Unexpected Result

If your GATM result flags a variant of potential clinical interest, the next step is to look at what your body is actually doing, not to repeat the gene test. The most useful companion data points fall into three groups:

• Kidney function: eGFR, cystatin C, urinary albumin-to-creatinine ratio, and standard creatinine give you a multi-angle view of how well your kidneys are filtering. A nephrologist becomes worth involving if these numbers drift, especially if there is family history of unexplained kidney disease.
• Muscle and statin response: creatine kinase and a lipid panel matter most if you are already on or considering a statin. A lipidologist or a pharmacist with pharmacogenetic experience can help interpret your result alongside other variants like SLCO1B1.
• Family history: unexplained kidney disease, statin intolerance, or early developmental issues in close relatives can shift how seriously to take an isolated GATM finding. A genetic counselor adds the most value when family history is significant.

Most GATM variants in the general population will not change your clinical care. The value of the test is in the small fraction of cases where the variant lines up with a real-world signal in your kidney, muscle, or family-history data.

When Results Can Be Misleading

Genetic test results themselves are stable, but their interpretation depends on the database used to classify variants. A variant called "uncertain" today may be reclassified as benign or pathogenic in a few years as more data accumulates. This is a normal feature of genetic testing, not a flaw in your specific result.

The other pitfall is overinterpretation. Carrying a GATM variant linked to statin response in one study does not mean you will or will not tolerate a statin. Carrying a variant linked to kidney disease risk in a Mendelian randomization study does not mean you will develop kidney disease. Genetic markers in this tier of validation shift probabilities. They do not predict individual outcomes.